“Today I got my second dose of an experimental coronavirus vaccine,” said Ian on twitter.
He went on to describe the pharmacist administering the vaccine: “I was looking at it once, and it brought a tear to my eye,” said the pharmacist, right before she injected me. “Just look at the color. It’s translucent — and it might save the world.”
Ian went on to describe the trial vaccine and dosage. “Just two” when asked if there were anymore doses needed. Social media response was both inquisitive and appreciative to Ian’s trial of the new coronavirus vaccine. Many called him an American hero.
Some users were skeptical however; “Is this an anti-spike vaccine? I almost signed up at Emory but then saw the paper about monkeys having far more severe coronavirus after anti-spike vaccination. Scary!” Daryl Rhye Jones replied back.
Ian responded to the Twitter question and stated that this particular trial was pre-fusion spike and urged that time was needed for concrete data science and analytics. According to Science Magazine, coronavirus binds to host cells through its trimeric spike glycoprotein, making this protein a key target for potential therapies and diagnostics.
Ian is the science communication manager at the Institute for Protein Design. He enjoys what appears to be a successful freelance writing career and he studies biotech and or what he refers to as “junk DNA” which is the science of how to turn plants into fuel.